<DOC>
	<DOC>NCT01594957</DOC>
	<brief_summary>This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of hepatic impairment to healthy subjects.</brief_summary>
	<brief_title>Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Inclusion criteria: Individuals with hepatic impairment only • Hepatic impairment evidenced by a ChildPugh score Mild hepatic impairment defined ChildPugh Class A (56 points) Moderate hepatic impairment defined ChildPugh Class B (79 points) Severe hepatic impairment defined ChildPugh Class C (1015 points). Healthy subjects only • Good health determined. Exclusion criteria: All Individuals A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QTinterval syndrome. Female subjects must be of non child bearing potential or use an effective method of contraception. Individuals with hepatic impairment History of drug or alcohol abuse within 3 months prior to dosing. History or presence of significant uncontrolled disease of any major organ class. Any surgical or medical condition other than hepatic impairment which might alter the drug metabolism. Healthy subjects History or presence of significant uncontrolled disease of any major organ class. Any surgical or medical condition other than hepatic impairment which might alter the drug metabolism. History or presence of hepatitis B or C and/or positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at screening. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>LCQ908,</keyword>
	<keyword>Hepatic Impairment,</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>